In last trading session, Apogee Therapeutics Inc (NASDAQ:APGE) saw 0.66 million shares changing hands with its beta currently measuring 2.23. Company’s recent per share price level of $34.55 trading at $0.6 or 1.77% at ring of the bell on the day assigns it a market valuation of $2.02B. That closing price of APGE’s stock is at a discount of -109.23% from its 52-week high price of $72.29 and is indicating a premium of 6.05% from its 52-week low price of $32.46.

Apogee Therapeutics Inc (NASDAQ:APGE) trade information

Upright in the green during last session for gaining 1.77%, in the last five days APGE remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $34.55 price level, adding 7.67% to its value on the day. Apogee Therapeutics Inc’s shares saw a change of -23.73% in year-to-date performance and have moved -4.72% in past 5-day. Apogee Therapeutics Inc (NASDAQ:APGE) showed a performance of -11.23% in past 30-days.

Wall Street analysts have assigned a consensus price target of 95 to the stock, which implies a rise of 63.63% to its current value. Analysts have been projecting 95 as a low price target for the stock while placing it at a high target of 95. It follows that stock’s current price would drop -174.96% in reaching the projected high whereas dropping to the targeted low would mean a loss of -174.96% for stock’s current value.

In 2025, company’s earnings growth rate is likely to be around 7.88% while estimates for its earnings growth in next 5 years are of -16.81%.

On the other hand, Vanguard Specialized-Health Care Fund and Fidelity Growth Company Fund are the top two Mutual Funds which own company’s shares. As of Oct 31, 2024 , the former fund manager was holding 2.0 shares of worth $69.1 million or 4.44% of the total outstanding shares. The later fund manager was in possession of 1.41 shares on Dec 31, 2024 , making its stake of worth around $48.69 million in the company or a holder of 3.13% of company’s stock.